Skip to main content
. 2013 Jun 1;6(3):329–337. doi: 10.1593/tlo.12490

Figure 2.

Figure 2

The SBK2 targeted contrast agent greatly improves the enhancement of LN-229 tumors. (A) Representative T 1-weighted axial 2D gradient images of LN-229 flank tumor-bearing mice before (pre-injection) and at 1, 5, 10, 20, and 30 minutes after the intravenous injection of ProHance, scrambled Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 at 0.1mmol Gd/kg [n = 7 tumors from four mice for ProHance; n = 11 tumors from six mice for both SBK2-Tris-(Gd-DOTA)3 and SBK2-Tris-(Gd-DOTA)3]. White arrow indicates tumor. (B) Axial 2D gradient images shown in A with heat map overlays on the tumor to indicate contrast intensity. Color-coded key indicates relative level of contrast intensity with red being the most intense.